Department of Neurology, Section of Developmental Neurobiology, University Hospital Würzburg, Würzburg, Germany.
Present address: Theodor-Kocher-Institute, University of Bern, Bern, Switzerland.
J Neuroinflammation. 2020 Oct 28;17(1):323. doi: 10.1186/s12974-020-01996-x.
The neuronal ceroid lipofuscinoses (CLN diseases) are fatal lysosomal storage diseases causing neurodegeneration in the CNS. We have previously shown that neuroinflammation comprising innate and adaptive immune reactions drives axonal damage and neuron loss in the CNS of palmitoyl protein thioesterase 1-deficient (Ppt1) mice, a model of the infantile form of the diseases (CLN1). Therefore, we here explore whether pharmacological targeting of innate immune cells modifies disease outcome in CLN1 mice.
We applied treatment with PLX3397 (150 ppm in the chow), a potent inhibitor of the colony stimulating factor-1 receptor (CSF-1R) to target innate immune cells in CLN1 mice. Experimental long-term treatment was non-invasively monitored by longitudinal optical coherence tomography and rotarod analysis, as well as analysis of visual acuity, myoclonic jerks, and survival. Treatment effects regarding neuroinflammation, neural damage, and neurodegeneration were subsequently analyzed by histology and immunohistochemistry.
We show that PLX3397 treatment attenuates neuroinflammation in CLN1 mice by depleting pro-inflammatory microglia/macrophages. This leads to a reduction of T lymphocyte recruitment, an amelioration of axon damage and neuron loss in the retinotectal system, as well as reduced thinning of the inner retina and total brain atrophy. Accordingly, long-term treatment with the inhibitor also ameliorates clinical outcomes in CLN1 mice, such as impaired motor coordination, visual acuity, and myoclonic jerks. However, we detected a sex- and region-biased efficacy of CSF-1R inhibition, with male microglia/macrophages showing higher responsiveness toward depletion, especially in the gray matter of the CNS. This results in a better treatment outcome in male Ppt1 mice regarding some histopathological and clinical readouts and reflects heterogeneity of innate immune reactions in the diseased CNS.
Our results demonstrate a detrimental impact of innate immune reactions in the CNS of CLN1 mice. These findings provide insights into CLN pathogenesis and may guide in the design of immunomodulatory treatment strategies.
神经元蜡样脂褐质沉积症(CLN 疾病)是致命的溶酶体贮积病,导致中枢神经系统的神经退行性变。我们之前已经表明,包含先天和适应性免疫反应的神经炎症会驱动棕榈酰蛋白硫酯酶 1 缺陷(Ppt1)小鼠的中枢神经系统中的轴突损伤和神经元丢失,Ppt1 小鼠是疾病的婴儿型的模型(CLN1)。因此,我们在这里探讨是否针对先天免疫细胞的药理学靶向可以改变 CLN1 小鼠的疾病结局。
我们应用 PLX3397(饮食中的 150ppm)治疗,PLX3397 是一种有效的集落刺激因子-1 受体(CSF-1R)抑制剂,用于靶向 CLN1 小鼠中的先天免疫细胞。通过纵向光学相干断层扫描和旋转棒分析以及视觉敏锐度、肌阵挛性抽搐和存活分析,非侵入性地监测实验性长期治疗。随后通过组织学和免疫组织化学分析来研究治疗对神经炎症、神经损伤和神经退行性变的影响。
我们表明,PLX3397 治疗通过耗竭促炎小胶质细胞/巨噬细胞来减轻 CLN1 小鼠的神经炎症。这导致 T 淋巴细胞募集减少,视网膜-视交叉系统中的轴突损伤和神经元丢失减少,以及内视网膜变薄和总脑萎缩减少。因此,该抑制剂的长期治疗也改善了 CLN1 小鼠的临床结局,例如运动协调、视觉敏锐度和肌阵挛性抽搐受损。然而,我们检测到 CSF-1R 抑制的性别和区域偏向性,雄性小胶质细胞/巨噬细胞对耗竭的反应更高,尤其是在中枢神经系统的灰质中。这导致雄性 Ppt1 小鼠在一些组织病理学和临床指标上的治疗效果更好,并反映了患病中枢神经系统中先天免疫反应的异质性。
我们的结果表明,先天免疫反应对 CLN1 小鼠的中枢神经系统有不利影响。这些发现为 CLN 发病机制提供了深入了解,并可能为免疫调节治疗策略的设计提供指导。